Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

Monica Iorfida; Vincenzo Bagnardi; Alessandra Balduzzi; Silvia Dellapasqua; Anna Cardillo; Alberto Luini; Mattia Intra; Ida Minchella; Paolo Veronesi; Giuseppe Viale; Aron Goldhirsch; Marco Colleoni

doi:10.1016/j.breast.2009.12.011

Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

Monica Iorfida, Vincenzo Bagnardi, Alessandra Balduzzi, Silvia Dellapasqua, Anna Cardillo, Alberto Luini, Mattia Intra, Ida Minchella, Paolo Veronesi, Giuseppe Viale, Aron Goldhirsch, Marco Colleoni

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/. neu positive breast cancer. Patients and methods: We tested a preoperative combination of trastuzumab with oral vinorelbine (oV) in pts with locally advanced (T2-T4 N0-3 M0) HER2-positive breast cancer. Trastuzumab was administered i.v q 3 wks and oV was administered at the dose of 55 mg/sqm on days 1 and 3 q 3 wks, for 8 courses. Pts with ER ≥ 10% tumors received endocrine therapy with letrozole 2.5 mg/day, plus monthly triptorelin if premenopausal. Results: Forty-five pts entered the study. The overall response rate (CR + PR) was 76% (95% CI: 60%-87%). pCR was observed in 4 pts (10%). Among ER-positive tumors 21/25 pts obtained a clinical response (84%) and two pts obtained a pCR (8%). Conclusions: The combination of trastuzumab and oral vinorelbine demonstrated encouraging activity in patients with HER 2 positive ER-positive tumors. Alternative strategies should be investigated in patients with endocrine non responsive disease.

Original language	English
Pages (from-to)	128-132
Number of pages	5
Journal	Breast
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.breast.2009.12.011
Publication status	Published - Apr 2010

Keywords

Breast cancer
Oral vinorelbine
Preoperative therapy
Trastuzumab

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.breast.2009.12.011

Cite this

Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. / Iorfida, Monica; Bagnardi, Vincenzo; Balduzzi, Alessandra; Dellapasqua, Silvia ; Cardillo, Anna ; Luini, Alberto ; Intra, Mattia ; Minchella, Ida ; Veronesi, Paolo ; Viale, Giuseppe; Goldhirsch, Aron; Colleoni, Marco.

In: Breast, Vol. 19, No. 2, 04.2010, p. 128-132.

Research output: Contribution to journal › Article › peer-review

Iorfida, Monica ; Bagnardi, Vincenzo ; Balduzzi, Alessandra ; Dellapasqua, Silvia ; Cardillo, Anna ; Luini, Alberto ; Intra, Mattia ; Minchella, Ida ; Veronesi, Paolo ; Viale, Giuseppe ; Goldhirsch, Aron ; Colleoni, Marco. / Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. In: Breast. 2010 ; Vol. 19, No. 2. pp. 128-132.

@article{35d0372b4da94ce9a15e296b818ca0ad,

title = "Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer",

abstract = "Background: Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/. neu positive breast cancer. Patients and methods: We tested a preoperative combination of trastuzumab with oral vinorelbine (oV) in pts with locally advanced (T2-T4 N0-3 M0) HER2-positive breast cancer. Trastuzumab was administered i.v q 3 wks and oV was administered at the dose of 55 mg/sqm on days 1 and 3 q 3 wks, for 8 courses. Pts with ER ≥ 10% tumors received endocrine therapy with letrozole 2.5 mg/day, plus monthly triptorelin if premenopausal. Results: Forty-five pts entered the study. The overall response rate (CR + PR) was 76% (95% CI: 60%-87%). pCR was observed in 4 pts (10%). Among ER-positive tumors 21/25 pts obtained a clinical response (84%) and two pts obtained a pCR (8%). Conclusions: The combination of trastuzumab and oral vinorelbine demonstrated encouraging activity in patients with HER 2 positive ER-positive tumors. Alternative strategies should be investigated in patients with endocrine non responsive disease.",

keywords = "Breast cancer, Oral vinorelbine, Preoperative therapy, Trastuzumab",

author = "Monica Iorfida and Vincenzo Bagnardi and Alessandra Balduzzi and Silvia Dellapasqua and Anna Cardillo and Alberto Luini and Mattia Intra and Ida Minchella and Paolo Veronesi and Giuseppe Viale and Aron Goldhirsch and Marco Colleoni",

year = "2010",

month = apr,

doi = "10.1016/j.breast.2009.12.011",

language = "English",

volume = "19",

pages = "128--132",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

AU - Iorfida, Monica

AU - Bagnardi, Vincenzo

AU - Balduzzi, Alessandra

AU - Dellapasqua, Silvia

AU - Cardillo, Anna

AU - Luini, Alberto

AU - Intra, Mattia

AU - Minchella, Ida

AU - Veronesi, Paolo

AU - Viale, Giuseppe

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2010/4

Y1 - 2010/4

N2 - Background: Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/. neu positive breast cancer. Patients and methods: We tested a preoperative combination of trastuzumab with oral vinorelbine (oV) in pts with locally advanced (T2-T4 N0-3 M0) HER2-positive breast cancer. Trastuzumab was administered i.v q 3 wks and oV was administered at the dose of 55 mg/sqm on days 1 and 3 q 3 wks, for 8 courses. Pts with ER ≥ 10% tumors received endocrine therapy with letrozole 2.5 mg/day, plus monthly triptorelin if premenopausal. Results: Forty-five pts entered the study. The overall response rate (CR + PR) was 76% (95% CI: 60%-87%). pCR was observed in 4 pts (10%). Among ER-positive tumors 21/25 pts obtained a clinical response (84%) and two pts obtained a pCR (8%). Conclusions: The combination of trastuzumab and oral vinorelbine demonstrated encouraging activity in patients with HER 2 positive ER-positive tumors. Alternative strategies should be investigated in patients with endocrine non responsive disease.

AB - Background: Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/. neu positive breast cancer. Patients and methods: We tested a preoperative combination of trastuzumab with oral vinorelbine (oV) in pts with locally advanced (T2-T4 N0-3 M0) HER2-positive breast cancer. Trastuzumab was administered i.v q 3 wks and oV was administered at the dose of 55 mg/sqm on days 1 and 3 q 3 wks, for 8 courses. Pts with ER ≥ 10% tumors received endocrine therapy with letrozole 2.5 mg/day, plus monthly triptorelin if premenopausal. Results: Forty-five pts entered the study. The overall response rate (CR + PR) was 76% (95% CI: 60%-87%). pCR was observed in 4 pts (10%). Among ER-positive tumors 21/25 pts obtained a clinical response (84%) and two pts obtained a pCR (8%). Conclusions: The combination of trastuzumab and oral vinorelbine demonstrated encouraging activity in patients with HER 2 positive ER-positive tumors. Alternative strategies should be investigated in patients with endocrine non responsive disease.

KW - Breast cancer

KW - Oral vinorelbine

KW - Preoperative therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=77951204959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951204959&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2009.12.011

DO - 10.1016/j.breast.2009.12.011

M3 - Article

C2 - 20117001

AN - SCOPUS:77951204959

VL - 19

SP - 128

EP - 132

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2

ER -

Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this